ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,802.82
      -0.67%
      US Tech 100
      20,333.60
      -1.10%
      Dow Jones
      41,603.07
      -0.61%
      Brent Oil
      64.525
      0.00%
      Bitcoin
      108,838.21
      1.43%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Acumen Pharmaceuticals Inc (ABOS)

      7. Acumen Pharmaceuticals Inc (ABOS) News

      Acumen Pharmaceuticals Inc

      Acumen Pharmaceuticals Inc (ABOS)

      NASDAQ
      1.02
      -0.01
      (-0.97%)
      Closed May 24 4:00PM
      15 min delayed - Upgrade to Realtime
      0.9918
      -0.0282
      (-2.76%)
      After Hours: 7:20PM
      15 min delayed - Upgrade to Realtime

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      ABOS News

      Official News Only

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 13 2025
      ABOS (-0.97%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 13 2025
      ABOS (-0.97%)

      Form ARS - Annual Report to Security Holders
      Edgar (US Regulatory)
      April 23 2025
      ABOS (-0.97%)

      Form DEF 14A - Other definitive proxy statements
      Edgar (US Regulatory)
      April 23 2025
      ABOS (-0.97%)

      Form S-8 - Securities to be offered to employees in employee benefit plans
      Edgar (US Regulatory)
      March 27 2025
      ABOS (-0.97%)

      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      Edgar (US Regulatory)
      March 27 2025
      ABOS (-0.97%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      March 27 2025
      ABOS (-0.97%)

      ABOS Discussion

      View Posts
      stockrafter stockrafter 1 week ago
      "Acumen Pharmaceuticals: Balancing Clinical Breakthroughs Against Financial Crossroads – A High-Stakes Alzheimer’s Play"

      Nice summary, hit on many of the good and bad issues with ABOS. As we know it's a risk, but the potential is enormous. At the current price, any investors should take the chances, buy some shares, and store them aware. Could lose it all, but at this price and not be a big loss, IMO, but if (when) it is proven, happy days ahead.

      https://www.ainvest.com/news/acumen-pharmaceuticals-balancing-clinical-breakthroughs-financial-crossroads-high-stakes-alzheimer-play-2505/
      👍️ 1
      Student of the Game Student of the Game 1 week ago
      VERY comprehensive presentation from yesterday.....

      https://investors.acumenpharm.com/static-files/b27addb9-6f6b-41f8-8d54-554818973383

      BTW; Company still has at the end of Q1 $297M cash!!!!
      👍️ 2
      Monksdream Monksdream 1 month ago
      ABOS, new 52 week low
      👍️0
      stockrafter stockrafter 1 month ago
      Guess post wasn't specific enough.....They are following the same path as in both are mAb, going after amyloid-beta-oligomers.

      Here is the latest list of current and upcoming ALZs drugs, a summary from the APPD conference....as you noted, there are quit a few.........

      https://www.delveinsight.com/blog/ad-pd-2025-conference-highlights

      Looks to be the start of another market down day, and ABOS follows. How low will it go. Relentlessly beating the heck out of the poor stock, but with the current turmoil going on in the FDA, and other agency, who knows if anything will get thru the regulatory process to market, in a timely fashion....Perplexing times......
      👍️ 1
      Student of the Game Student of the Game 1 month ago
      There are a lot of people that have had margin calls in this ugly market resulting from other positions. As Acumen is not a marginal security it provides 100% cash release on a sale.

      IMO; this is an amazing opportunity to buy shares that are just being thrown away. I'm repeating myself, but Acumen has over $3/share in CASH, doesn't need money to complete this Phase II trial for probably the biggest and most needed disease on this planet!!

      If you've read all the information on their website, and listened to all their presentations and read the 10K, you would understand what the value of this Company really is.

      Patience is a virtue. This Company can literally go from this current ridiculous price to $200/share over the next 2 years. I can't find a better investment!!!

      GLTA!!
      👍️ 2
      Monksdream Monksdream 1 month ago
      ABOS, new 52 week low
      👍️0
      Student of the Game Student of the Game 1 month ago
      Promis is on a different path and has just recently started a Phase I clinical trial and are (IMO) at least 2-3 years behind Acumen in the clinic. Acumen has powerful Phase I results and was FDA cleared to commence a Phase II trial which started enrolling in May 2024 that is now FULLY enrolled!!

      Promis is also not well funded and is having difficulty raising equity.

      BTW; I hope there are multiple drugs that could help this horrible disease!!

      GLTA!!!
      👍️ 1
      stockrafter stockrafter 1 month ago
      Appears to be on the same path.........

      "Exploring a vaccine-based approach to targeting Aß oligomers in Alzheimer’s disease"

      👍️ 1
      Student of the Game Student of the Game 1 month ago
      Noi perplexing.... This latest selling has nothing to do about Acumen. It has to do with someone yesterday had a margin call and needed money. As ABOS is not marginal it provides 100% cash to the desperate seller. This provides a special "opportunity" to a buyer; unfortunate for the seller, I'm sure that's what happened.

      Be confident; this Company is advancing great science to help the Alzheimer's population which is a gigantic market and ABOS has the funding in place to complete this Phase II trial.

      GLTA!!
      👍️ 1
      stockrafter stockrafter 1 month ago
      Yes can actually say, "Been there, done that," so much good info out there, yet...............Looks like stock got punished today for escaping the downward spiral yesterday, by going up a few pennies. Well took those pennies back and more today.....Go figure.....perplexing it is........
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Excellent information.

      I also suggest reading the first 15 pages of Acumens 10K filing. Great information there too.
      👍️ 1
      stockrafter stockrafter 2 months ago
      All of Acumen's JPAD 2025, and ADPD 2025 Posters and articles, have been posted on their publication website page. The details and range of the info on Sabirnetug is incredible. Well worth skimming thru them all, even if the science is initially overwhelming, it starts making sense. This company is more then a one drug company, they are an Alzheimer research machine. So please stop selling, it is just to perplexing....👍️..

      https://acumenpharm.com/document-library/
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      Like all of biotech.

      However, not all of biotech has completed enrollment is a phase II trial of a VERY impressive Alzheimers drug and also has funding to complete the trial without the need for additional monies.

      This is a prime example of the baby being thrown out with the bath water. I was a buyer yesterday!!
      👍️ 1
      Monksdream Monksdream 2 months ago
      ABOS, new 52 week low
      👍️0
      Student of the Game Student of the Game 2 months ago
      Acumen issues press release....

      https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-showcases-ptau217-trial-screening
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Very upbeat Y/E CC this morning.

      At Y/E Acumen had $231M cash and equivalents or over $3.50/per share in cash. Certainly more than enough money to complete the Phase II trial!!

      Pura Vida!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      "Can we hope for more then a penny rise on the news........" ......Guess not......😟
      👍️ 1
      stockrafter stockrafter 2 months ago
      Some mighty fine words...."statistically significant amyloid plaque reduction compared to placebo at higher dose multiple-ascending dose cohorts evaluated in the study"

      Should be an interesting Annual CC tomorrow.......
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      The Phase 1 INTERCEPT-AD clinical trial demonstrated sabirnetug was generally well-tolerated with low overall rates of ARIA-E. The trial also showed dose- and exposure-dependent target engagement and statistically significant amyloid plaque reduction compared to placebo at higher dose multiple-ascending dose cohorts evaluated in the study.

      These results were after only 3 months of being treated with Sabirnetug in a phase I trial. One might expect significantly greater results in a 18 month trial!! This is a next generation drug!!

      Good luck to all the patients!!
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Months AHEAD of schedule!!!!

      Every milestone has been hit on or ahead of schedule!!

      GLTA!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      "Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease"

      March 26, 2025 at 8:01 AM EDT

      "We look forward to sharing topline results in late 2026 and advancing sabirnetug as a next-generation treatment for Alzheimer’s disease.""

      Can we hope for more then a penny rise on the news........

      https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-completes-enrollment-altitude-ad-phase-2
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      There are 500,000 newly diagnosed Alzheimers patients in the US each year. That number is growing due to the aging of our population and new diagnostic blood tests which are expected to increase the actual numbers significantly.

      The market is enormous and the 2 FDA approved drugs are being shunned as their side effects create a significant health risk.

      Siburnitug showed a MUCH improved safety profile and showed efficacy in a 3 month Phase I trial. My expectations for the current Phase II trial are VERY high!!

      If this drug shows what I'm hoping for in the Phase II trial; I can assure you BIG PHARMA will be all over this Company.

      GLTA!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      Yes, that has been posted since, "Last Update Posted 2024-12-1." ....made note of it earlier.....been waiting for a comment from Acumen.....Maybe during the Q4 cc.....who knows....See no reason why they could not have posted the SC vs IV news two days earlier so Dan could have discussed it......

      This doesn't help........

      https://abcnews.go.com/Technology/wireStory/researchers-find-hint-delay-alzheimers-symptoms-now-prove-119968700
      👍️ 1
      stockrafter stockrafter 2 months ago
      Minusha....at current rate stock will soon be de-listed.......Someone needs to explain how this low price is possible? Who is selling all those cheap shares?......
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      A look a ClinicalTrials.gov now shows that Sabirnetug is an active trial and NOT recruiting patients. IMO; this could only mean that the trial is now FULLY ENROLLED!!

      https://clinicaltrials.gov/study/NCT06335173?term=NCT06335173&viewType=Table&rank=1

      I would expect a Company announcement to this effect in the very near future!!

      Hitting every milestone on or before expectation!!

      GLTA!!!
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Forget the minusha, and look at the big picture. Acumen is meeting all its milestones on time. They have more than enough cash to finish this Phase II trial. If these results turn out to be what we all are hoping for, Acumen will be bought out by big Pharma for $200+/share.

      I have never seen in all my years on/around Wall Street a better Rick vs Reward scenario than this.

      Two MAJOR industry presentations coming up and VERY soon an announcement of full enrollment in the Phase II trial.

      Could not be looking better. Take advantage of this SALE on shares!!!

      GLTA!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      Losing enthusiasm after today's disappointing close......Guess the only person more disappointed would be Dr O'Connell, three presentations in two days, a great PR, and what does he get for it.........a penny.......☹️.......It makes one give up investing in stocks.......
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Ticking off each milestone on or before scheduled date.

      Next up: Full Enrollment Phase II trial!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      Great.....its a start......I liked this....knew O.Connell was holding back info.....

      "We are pleased that the results of our initial clinical study support further clinical development of sabirnetug administered subcutaneously, underscoring the potential for increasing patient convenience of this formulation relative to intravenous treatment,” said Daniel O’Connell, Chief Executive Officer of Acumen. “The timely completion of this study highlights the strength of our clinical team and partners, and our commitment to advancing our clinical pipeline efficiently and effectively. Based on these data, we believe that further development of subcutaneous sabirnetug as a more convenient administration option for patients is warranted.”"
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

      https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-announces-topline-results-phase-1-study

      GLTA!!
      👍️ 1
      stockrafter stockrafter 2 months ago
      Well, will need to agree with you again, another nice discussion......best thing, at most, in 9 working days the IV-SC report will be posted....then hopefully the perplexing low SP will come to an end....
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      Today's Stifel interview was equally interesting and worth watching too. O'Connell exudes EXTREME confident.

      I liked to answer to the question on what is the mechanism for Sabirnitug in removing plaque. I think today's interviewer also did an excellent job.
      👍️ 1
      stockrafter stockrafter 2 months ago
      Agree, thought Mr O'Connell did a bang up job, also thought the interviewer did a fine job. Seemed to know Acumen well, and asked some good questions. Liked the discussions on the SC trials. Could tell Dan was holding back, it was obvious he just wanted to say more. Was encouraged when he just had to make note that info on the IV vs Sc trial will be out by the end of Q1 2025…so within two weeks, great. Will bet they present news on the new AI deal when they provide update on the P2 SC trial. Have to also agree, the presentations in early April should be much more interesting after the SC news, and the annual report.

      SP should be heading up for a change or will be more perplexed.....
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      Just listened to Acumen CEO Dan O'Connell have a sit down chat with the UBS analyst. It was an excellent interview and the replay is already available on Acumen's website in the Investor tab.

      The CEO mentioned that they have previously stated that the Altitude Phase II trial enrollment would be a first half 2025 event and then went on to say that "enrollment was going quicker and more rapidly than expected". Which translates to me that they are close to full enrollment and I'm looking for an announcement to that effect at one of the big conferences that takes place during the first 2 weeks of April!!

      GLTA!!
      👍️ 2
      stockrafter stockrafter 2 months ago
      Going to be an informative couple of weeks with all the up coming presentations, will be listening to all of them. It will be a good change to be perplexed on how high and fast the SP moves back up.......👍️...
      👍️ 2
      Student of the Game Student of the Game 2 months ago
      Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
      https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-present-during-international-conference
      👍️ 1
      stockrafter stockrafter 2 months ago
      Great, would be a good time to present data from the IV/SC trial, an update on the future SC/AI trial, and a mid-term update on the current P2 trial......an investor can hope.......They will also need to post annual report by end of month....so should be getting some new info at some point....Will be listening and looking........
      👍️ 1
      Student of the Game Student of the Game 2 months ago
      Acumen to Participate in Two Investor Conferences:

      https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-upcoming-investor-conferences
      👍️ 1
      stockrafter stockrafter 3 months ago
      Up three days in a row can it go for 4 days Went from its record low of 1.15 to 1.24 averaging 3 cents/day, great, at this rate in 30 trading days it will be back to 2.15 or so…..so perplexingly manipulated.

      Oh well things will improve, and this small tid-bit of info is encouraging……progress on P2 reported……but will probably need to wait for the AAN Annual Meeting, taking place April 5–9, 2025, for more info…....read the abstract and disclosure………back to looking….

      https://index.mirasmart.com/AAN2025/SearchResults.php?q=sabirnetug
      👍️ 2
      Student of the Game Student of the Game 3 months ago
      Bought more today!! Price hasn't shaken my confidence.

      $2.83/ share in CASH PLUS GREAT drug completing Phase II enrollment!!

      PURA VIDA!!!
      👍️ 1
      Monksdream Monksdream 3 months ago
      ABOS, new 52/week low
      👍️0
      stockrafter stockrafter 3 months ago
      One thing for certain, "Time will tell".....while still perplexed and waiting, a nice subtle encouraging comment from the CEO helps..

      21 Feb 2025, Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

      “In 2025, I expect the biopharma industry to build on the strong momentum of recently approved treatments for Alzheimer’s by prioritizing the development of new Alzheimer’s therapies with improved safety profiles, particularly lower ARIA [amyloid-related imaging abnormalities, a side-effect of amyloid-beta therapies] rates,” predicted Daniel O’Connell, CEO of Acumen Pharmaceuticals.

      “By focusing on novel approaches that enhance safety and broaden accessibility, there is potential to reach more patients and significantly improve their quality of life. Additionally, preferentially targeting other components of the Alzheimer’s disease pathway, such as toxic amyloid beta oligomers, offers an opportunity for next-generation therapies that can be used independently or in combination, providing greater efficacy and differentiated treatment outcomes. This progress of further innovation ensures that more patients benefit from treatments that could greatly enhance their quality of life,” O’Connell added.
      👍️ 2
      Student of the Game Student of the Game 3 months ago
      BTW; I predict, there will be MANY days when this stock is UP more than it's current price in one day!!

      PURA VIDA!!
      👍️ 1
      Student of the Game Student of the Game 3 months ago
      Stockrafter; Great series of articles.

      One day as I've said this stock has a $200 potential. That's what investing is about. Risk/Reward here is Ridiculous!!!

      Keep the faith!! I pray that Sabirnitug has a MAJOR positive effect on Alzheimers disease. It will be a game changer for humanity!!
      👍️ 1
      stockrafter stockrafter 3 months ago
      No, do not think they are going head to head, but it is in the same game, so keeping track on it, while waiting. The pic of the auto-injector was interesting. It is the same AI Biogen uses for the Plegridy Pen, fwiw.

      Enough on that, check out the info below……it is eye opening information……

      The beginning of the story…… https://news.northwestern.edu/stories/2019/01/a-new-approach-to-alzheimers-disease/

      Developer of Sabirnetug.……smart dude…. https://neurobiology.northwestern.edu/people/core-faculty/klein-william.html

      The website…check out the research and other links……good stuff…. https://kleinlab.org/

      Write up on the impressive team……. https://news.weinberg.northwestern.edu/2024/01/29/neuroscientist-william-kleins-purpose-and-perseverance-continues-inspiring-a-new-wave-of-efforts-to-combat-alzheimers-disease/

      “Acumen is among the foremost drug discovery companies attacking amyloid beta oligomers and its most promising therapeutic, ACU193, derives from an antibody program initiated in Klein’s research lab decades ago.”

      So now even more perplexed on the share price..........but one of these days.....no doubt.......
      👍️ 2
      Student of the Game Student of the Game 3 months ago
      You are making the mistake to think that Acumen's drug; Saburnitug is competing head on with Leqembi. We are in a Phase II trial to try and prove that Saburnitug is a BETTER drug AND has SIGNIFICANTLY FEWER SERIOUS side affects that Leqembi.

      The action of mechanism is much different in Saburnitug!!

      I understand enrollment has been rapid and I would expect to hear that full enrollment has been reached considerably before the end of the first half of 2025 which was the Company's target date.

      PATIENCE IS A VIRTUE!!!

      FYI; the biotech market has been weak due to the new administration and the unknowns of RFK Jr.

      GLTA!!!
      👍️ 2
      stockrafter stockrafter 3 months ago
      Well this is not helping...but it is what it is, competition doesn't wait......need info from management to reverse the relentless decline.......

      "submitted applications for approval of lecanemab in 17 countries and regions. Additionally, the FDA accepted Eisai's Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025."

      https://media-us.eisai.com/2025-01-26-FDA-Approves-LEQEMBI-R-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease

      https://alzheimersweekly.com/leqembi-autoinjector-to-treat-alzheimers-in-seconds-not-hours/
      👍️ 1
      stockrafter stockrafter 3 months ago
      Some interesting info from their partner on SC injection. The partner company reported signing a small volume AI deal with a company…Highly suspect it was Acumen…..It fits the timeline, since a deal needs to be signed before announcing the upcoming P2 SC trial, which will also be validating the AI SC IMO…..

      Yet they can still beat the price down....so Perplexing to this small investor.......

      New article on the P1 trial, more of the same but in detail....…. https://www.sciencedirect.com/science/article/pii/S2274580725000263

      Interesting short video on the two current ALZ drugs….given by IV, 1x mn or 2x mn, at $25,000yr……All the more reason for SC injection in 3 seconds....…

      https://www.kare11.com/article/news/health/another-treatment-those-affected-alzheimers-disease/89-d293e960-867f-4f71-9e61-91cf03d23a2a
      👍️ 2
      stockrafter stockrafter 3 months ago
      Thanks the posts, it all sounds good, which is why it is so perplexing to me, as to who is selling all those shares over the past few months? It is easily noticeable on the Yahoo chart, that since the big drop back on 11/12/2024 the volume is relatively higher than past, and the price keeps falling. Roughly 400,000 for 40 days, is 16,000,000 shares, all below $2.50, with Yahoo Finance showing only 34 million in the float. Perplexing!

      As a small investor, one can only buy so many shares, or risk a large percentage of the portfolio in one stock. Would have been nice, to have the technical skills, to surmise the SP would drop so low, certainly would have more share at a lower price. Still with an expected share price greatly exceeding my expectation of low teens, waiting will not be a problem. Unfortunately it is down today already, with high volume. Perplexing!
      👍️ 1
      Student of the Game Student of the Game 3 months ago
      BTW; at the end of September there were approximately 60 million shares outstanding.

      Cash and marketable securities were $207M. Let's be conservative and say that there was $170M+ at Y/E. That means there was $2.83/share in CASH equivalents at Y/E. What is their research results to date worth? What about value for getting the drug into this Phase II trial?

      This Company is worth WAY IN EXCESS of where it is currently trading.


      GLTA!!!
      👍️ 1

      Your Recent History

      NASDAQ
      ABOS
      Acumen Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads